Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25161231 | 0.87 | HDAC2 (0.58) | HDAC1HDAC2HDAC3KCNH2HDAC4 | |
| SCHEMBL25161874 | 0.83 | HDAC2 (0.47) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL25161315 | 0.83 | HDAC1 (0.51) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL23517831 | 0.82 | HDAC1 (0.53) | HDAC1HDAC2HDAC3 | |
| SCHEMBL25161862 | 0.82 | HDAC2 (0.46) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL25161000 | 0.82 | HDAC1 (0.50) | HDAC1HDAC2HDAC3KCNH2P2RX7 | |
| SCHEMBL25161266 | 0.82 | HDAC1 (0.58) | HDAC1HDAC2HDAC3KCNH2HDAC8 | |
| SCHEMBL25161246 | 0.81 | HDAC2 (0.57) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL25161760 | 0.81 | HDAC1 (0.47) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL25161114 | 0.81 | HDAC2 (0.51) | HDAC1HDAC2HDAC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119479-A1 | A HISTONE DEACETYLASE INHIBITOR HAVING A NITROGEN-CONTAINING AROMATIC HETEROCYCLYL GROUP | SHIONOGI & CO., LTD. (JP) | 2023-04-20 | — | — | US | disclosed |
| WO-2021117759-A1 | HISTONE DEACETYLASE INHIBITOR HAVING NITROGEN-CONTAINING AROMATIC HETEROCYCLIC GROUP | 塩野義製薬株式会社 | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119479-A1 | A HISTONE DEACETYLASE INHIBITOR HAVING A NITROGEN-CONTAINING AROMATIC HETEROCYCLYL GROUP | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.